OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Results of Operations and Financial ConditionItem 2.02 — Results of Operations and Financial Condition.
On November 8, 2017, OpGen, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2017. The full text of such press release is furnished as Exhibit 99.1 to this report.
Item 9.01 — Financial Statements and Exhibits.
| 99.1 |
Press Release, dated November 8, 2017, issued by OpGen, Inc.
|
EXHIBIT INDEX
|
Exhibit No. |
Document |
|
99.1 |
Press Release, dated November 8, 2017, issued by OpGen, Inc. |
OPGEN INC ExhibitEX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1 OPGEN REPORTS 2017 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Affirms plans to release Acuitas® AMR Gene Panel in the first quarter of 2018 Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG,…To view the full exhibit click here
About OpGen, Inc. (NASDAQ:OPGN)
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.